News Category
In vitro ADME studies are becoming essential for efficient drug development, helping to identify promising candidates early and avoid costly late-stag...
Anthropic is expanding into pharmaceutical research with AI-driven drug development initiatives, signaling a significant shift in how technology may r...
Telomir Pharmaceuticals announced the publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-...
NanoViricides announced that the Democratic Republic of Congo's Pillar Committee has approved its proposal for a Phase II clinical trial of NV-387 Ora...
SureNano Science Ltd. initiates GLP toxicology and pharmacology programs for its lead obesity drug GEP-44, a necessary step before IND application and...
Optimi Health Corp. has shipped naturally derived psilocybin to the United Kingdom for a planned Phase 2 clinical trial, marking a key milestone in in...
Onco-Innovations Limited has initiated process development and intermediate scale-up for ONC010's active ingredient, marking a key step toward IND-ena...
Onco-Innovations Ltd. is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways, supported by five patents and...
Quantum BioPharma reports positive Phase 1 trial results for its LUCID-MS therapy targeting myelin repair in multiple sclerosis, addressing a critical...
TransCode Therapeutics will host its first R&D webcast on June 18, 2026, to discuss its Phase 2a trial of TTX-MC138 in colorectal cancer and broader p...
Onco-Innovations Limited has signed a non-binding letter of intent with Nanosoft Polymers to support development of its oncology candidate ONC010 and ...
Oncotelic Therapeutics will showcase its PDAOAI platform, built on Qdrant infrastructure, which accelerated two drug candidates from concept to IND fi...
Lifordi's novel subcutaneous glucocorticoid antibody-drug conjugate shows safety and anti-inflammatory activity without cortisol suppression in health...
New findings from HighTide Therapeutics show that HTD1801 improves renal function and protects podocytes, potentially offering a disease-modifying the...
Quantum BioPharma is advancing a novel multiple sclerosis therapy through its subsidiary Lucid Psycheceuticals and expanding into the alcohol health m...
Kairos Pharma announces plans to acquire CL-741, a Phase 1-ready oral c-MET kinase inhibitor, to expand its oncology pipeline, while advancing clinica...
Helix BioPharma Corp. closes a C$3.67 million private placement of convertible debentures to fund working capital and drug development programs.
Oncotelic Therapeutics announces the expansion of its Phase 1b clinical program for Sapu003 and the appointment of Global Clinical Trials to lead inte...
Revolution Medicines' new pill daraxonrasib targets KRAS mutations and has reportedly doubled survival in early trials, offering hope against a notori...
Lantern Pharma's LP-300 combination therapy shows improved progression-free survival in L858R-mutant non-small cell lung cancer patients, with FDA-cle...
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial success of unbuzzd, with an upcoming Phas...
New data presented by Tonix Pharmaceuticals reveals that despite guidelines discouraging opioid use, nearly 40% of fibromyalgia patients are prescribe...
Tonix Pharmaceuticals announced publication of positive Phase 1 data for its anti-CD40L monoclonal antibody TNX-1500, showing favorable safety and tol...
Onco-Innovations Limited reports progress in intermediate-scale manufacturing for its nanoparticle-formulated oncology candidate ONC010, moving toward...
SureNano Science Ltd. is advancing its GLP-1-based therapeutic GEP-44 through FDA pathways, targeting the rapidly growing obesity and metabolic diseas...
NanoViricides announced the closing of a $2 million registered direct offering with a single institutional investor, with proceeds expected to support...
Lantern Pharma announced FDA acceptance of protocol amendments for its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-sma...
SureNano Science Ltd. is advancing GEP-44, a patented triple agonist peptide targeting obesity and metabolic disease with improved tolerability and po...
Oncotelic Therapeutics announced first-quarter financial results and progress across its oncology, AI drug development, and CNS delivery initiatives, ...
Annovis Bio announced first-quarter 2026 progress including 85% enrollment in its pivotal Phase 3 Alzheimer’s trial and 40% enrollment in its Parkinso...
NanoViricides reported progress in its broad-spectrum antiviral NV-387, including regulatory approval for a Phase II MPox trial in the Democratic Repu...
NanoViricides has entered into a securities purchase agreement for a registered direct offering expected to generate approximately $2 million, with pr...
SureNano Science Ltd. announced its placement in a BioMedWire editorial highlighting its subsidiary GlucaPharm's novel triple agonist peptide GEP-44 f...
CNS Pharmaceuticals reported first-quarter 2026 financial results, highlighting progress in its shift to an acquisition-driven growth model, bolstered...
Oncotelic Therapeutics and Sapu Nano have dosed the first patient in a Phase 1b trial of Sapu003, a novel IV formulation of everolimus, aiming to impr...
GeoVax Labs emphasizes the strategic role of its Gedeptin platform in enhancing checkpoint inhibitor efficacy against immunologically cold tumors by r...
SureNano Science Ltd. has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, targeting the rapidly growin...
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide aimed at improving efficacy, tolerability and delivery flexibility in the r...
Oragenics Inc. advances its Phase IIa clinical trial for ONP-002, a concussion treatment, with enrollment at a second site and a target data readout b...
NanoViricides' NV-387 granted Orphan Drug Designation by FDA for measles, offering incentives and supporting development amid rising global outbreaks.
Telomir Pharmaceuticals received FDA IND clearance to initiate a Phase 1/2 clinical trial for Telomir-Zn in advanced or metastatic triple-negative bre...
Tonix Pharmaceuticals announced Phase 1 results for TNX-4800, a monoclonal antibody targeting Lyme disease, and plans to initiate a Phase 2 study in 2...
GeoVax Labs outlines near-term milestones for its oncology drug Gedeptin, including a planned Phase 2 trial in head and neck cancer and pursuit of par...
ARMR Sciences completed a private placement to fund its fentanyl vaccine, which is backed by the U.S. Department of Defense and aims to prevent fatal ...
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with M...
